GO
Loading...

Pharmaceuticals

More

  • AstraZeneca Gets New US Approval for Seroquel XR Friday, 16 Nov 2007 | 8:58 AM ET

    AstraZeneca said on Friday that U.S. health regulators had approved Seroquel XR, an extended-release version of one of its top-selling drugs, as a maintenance treatment for adult schizophrenia patients.

  • J&J to Focus Beyond Traditional Lines of Business Thursday, 15 Nov 2007 | 1:16 PM ET
    Johnson & Johnson

    Health care products maker Johnson & Johnson, faced with lagging sales of some top products, said Thursday it would create three new units to boost prospects.

  • Buy Wyeth? Tuesday, 13 Nov 2007 | 10:39 AM ET

    What's the best reason to own a pharma stock right now? Consistency in the face of recession.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • State of the Market Tuesday, 13 Nov 2007 | 10:34 AM ET

    Stay in the game, Cramer says, but play it cautious.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Roche Says Avastin Study Misses Endpoint Tuesday, 13 Nov 2007 | 5:54 AM ET

    Roche on Tuesday said a late-stage study of its cancer drug Avastin in combination with gemcitabine chemotherapy and Tarceva for pancreatic cancer did not meet the primary endpoint for survival.

  • The surprising Vioxx settlement brought me back to the office today in the middle of my vacation--I could've literally phoned it in as I did on "Squawk Box" this morning, but as long as I was in town, I'm too hard core to stay at home working around the house when a big story like this one breaks on my beat.

  • Warnings Strengthened for Amgen, J&J Anemia Drugs Thursday, 8 Nov 2007 | 1:50 PM ET

    The warning labels have been strengthened on anemia drugs made by Amgen Inc and Johnson & Johnson to reflect concerns they may increase the risk of heart attacks, stroke and death, the companies and U.S. regulators said on Thursday.

  • Germany's Bayer will cut 1,500 jobs at its plastics unit -- 10 percent of the division's workforce -- despite a higher-than-expected rise in group quarterly operating profit, it said on Tuesday.

  • Novartis Diabetes Drug Faces Further Delays Tuesday, 6 Nov 2007 | 3:44 AM ET
    Novartis

    Novartis has found safety problems in higher doses of its key Galvus diabetes drug and will revise prescribing recommendations before launching in Europe.

  • Bayer Suspends Trasylol For Now, Awaits Study Monday, 5 Nov 2007 | 11:13 AM ET

    Germany's Bayer has suspended temporarily the global marketing of its anti-bleeding drug Trasylol, which has been linked to a higher risk of death, pending final results of a Canadian study for the medicine.

  • As I begin my vacation, I wanted to tell you about a story I did that's airing while I'm away on the new edition of CNBC's "Business Nation" this Wednesday (November 7th) at 9 p and midnight ET. It's about the increasingly strained relationship between drug sales reps and doctors.

  • Pharma Stocks To Watch On Monday (And My Time Off) Sunday, 4 Nov 2007 | 12:57 PM ET

    I'm taking some much needed time off for a couple of weeks. Actually, our scheduling guru at CNBC, Alex Crippen, told me if I don't use all of the days I've accumulated by the end of next month, I'll lose them. I consider myself a hard worker, but I'm not that generous. So, off I go.

  • Vertex In The "Vortex" Over Hepatitis C Test Results Friday, 2 Nov 2007 | 12:04 PM ET
    Vertex

    There's a flurry of selling going on this morning in shares of the biopharma Vertex Pharmaceuticals. Overnight the embargo lifted on the long awaited results of the company's mid-stage test on a new type of Hepatitis C drug. Two studies show that six months out 60% and 65% of patients had no detectable virus in their blood.

  • Zocor

    This morning we got more evidence about the havoc generic Zocor is wreaking on all of the companies that make brand-name statins--the pills to fight cholesterol. AstraZeneca is the latest casualty. On a down day in the markets AZN is one of the biggest losers in the sector.

  • Shire's Third-Quarter Earnings Top Forecast Thursday, 1 Nov 2007 | 10:46 AM ET

    Britain's Shire beat forecasts with a 32 percent rise in third-quarter underlying earnings on Thursday and said its new hyperactivity drug, Vyvanse, had been well received by doctors and patients.

  • Genentech's Avastin: An "Eye Opening" Disclosure? Thursday, 1 Nov 2007 | 9:44 AM ET

    Yet another chapter in the unfolding saga of Genentech's Avastin being used instead of Lucentis to treat age-related macular degeneration (AMD). The other day I blogged about the new "Open Letter" on the company's homepage announcing that it's delaying the implementation of its attempted crackdown on the cheaper, similar cancer drug being used...

  • AmerisourceBergen Quarterly Earnings Tumbles 28% Thursday, 1 Nov 2007 | 8:28 AM ET

    AmerisourceBergen, one of the top U.S. drug wholesalers, said Thursday that quarterly earnings fell 28 percent as it took a write-down on its tetanus-diphtheria vaccine inventory.

  • Crestor Competition Overshadows AstraZeneca Results Thursday, 1 Nov 2007 | 8:11 AM ET

    AstraZeneca profits fell 14 percent in the third quarter, hit by competition from cheap generics plus acquisition and restructuring charges, the Anglo-Swedish drugmaker said on Thursday.

  • On the Line: Nastech Pharma CEO Dr. Stephen Quay Wednesday, 31 Oct 2007 | 8:02 PM ET

    The chief executive talks up his approach to business, a pesky payment owed by Procter & Gamble and why the company will succeed where rivals have failed.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Eli Lilly: Will They Get Lucky With 'One A Day' Cialis? Wednesday, 31 Oct 2007 | 3:36 PM ET
    Eli Lilly

    Today's the day Eli Lilly was expected to get a Food and Drug Administration decision on the first-ever one-a-day impotence drug. Right now, the company sells Cialis for use as needed. But men could pop this one every day--like an aspirin or multi-vitamin--so the drug would always be "on boa